This week's roundup of Houston innovators includes Kevin Coker of Proxima CRO, Gaurab Chakrabarti of Solugen, and Phil Sitter and Chris Chomenko of RepeatMD. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to four local innovators across industries — from marketing tech to synthetic biology — recently making headlines in Houston innovation.

Kevin Coker, CEO and co-founder of Proxima CRO, and Gaurab Chakrabarti, CEO and co-founder of Solugen

First Bight VC named two Houstonians to its board. Photos courtesy

First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups founded by Veronica Wu in January, has named two new board members: Gaurab Chakrabarti, co-founder and CEO of Solugen, and Kevin Cocker, co-founder and CEO of Proxima CRO.

"We are excited to announce the addition of Dr. Gaurab Chakrabarti and Kevin Cocker," Wu says in a press release. "These two advisors are experts in their respective fields of medicine and biotechnology. They are proven leaders of Houston-based companies, which is key to our overall growth strategy, as we seek to establish Houston as a geographic center for innovation in Synthetic Biology." Click here to read more.

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko join the Houston Innovators Podcast to explain how they are revolutionizing the aesthetics industry. Photos courtesy

Houston restaurateur pivoted his restaurant marketing business amid the pandemic — to a growing industry: aesthetics. Phil Sitter took the idea and tech he created with VIPInsiders to launch RepeatMD, a customizable marketing and fintech platform focused on the aesthetics industry, which includes plastic surgeons, dermatologists, etc.

Sitter, who serves as the company's CEO, says once he dived into learning about the industry, he found out these types of business are seeing incredible growth following the pandemic.

"They call it the 'Zoom boom' — everyone saw themselves on Zoom daily and decided to invest in themselves and their facial treatments." says Chris Chomenko, vice president of sales for the company, on the Houston Innovators Podcast.

"And they had the time," Sitter adds. "When you think about aesthetic procedures — whether its invasive or non-invasive, it takes time for recovery." Click here to read more.

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko join the Houston Innovators Podcast to explain how they are revolutionizing the aesthetics industry. Photos courtesy

Houston innovators find 'perfect storm' for fintech and marketing platform

Houston innovators podcast episode 129

Phil Sitter saw fast growth and adoption from his restaurant rewards platform he founded in 2019, but when the pandemic hit, he had to go back to the drawing board to find a growing industry that needed to be disrupted by his technology. And he did.

Sitter, a Houston restaurateur, originally founded VIPInsiders to help his restaurants — and later, licensing the technology out, other Houston eateries too — reward loyal patrons who continue to come in. However, in 2020, Sitter considered a pivot.

"We realized the restaurant industry may never be the same, and we asked ourselves who could be an ideal client," Sitter says on the Houston Innovators Podcast.

This pivot ended up creating RepeatMD, a customizable marketing and fintech platform focused on the aesthetics industry, which includes plastic surgeons, dermatologists, etc.

Sitter, who serves as the company's CEO, says once he dived into learning about the industry, he found out these types of business are seeing incredible growth following the pandemic.

"They call it the 'Zoom boom' — everyone saw themselves on Zoom daily and decided to invest in themselves and their facial treatments." says Chris Chomenko, vice president of sales for the company.

"And they had the time," Sitter adds. "When you think about aesthetic procedures — whether its invasive or non-invasive, it takes time for recovery."

After initially branching out into the field, Sitter says they are now onboarding up to 200 new locations a month, providing med spas around the world the ability to reward returning customers, as well as inform them on the breadth of options the facility offers. RepeatMD has expanded its team to 50 people and is eyeing seed funding this summer.

"Some things had to work out perfectly in order," Chomenko says, "for this perfect storm of perfect timing. Whenever you talk about entrepreneurs and how much of it was luck and how much of it is hard work, we really have attribute a lot of our success to being there with the right idea, in the right place, at the right time."

Sitter and Chomenko share more about the future of RepeatMD on the podcast episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

RepeatMD offers its clients rewards-based software and is expanding with a new fintech tool. Photo via Getty Images

Fast-growing Houston software startup expands with fintech model

innovative marketing

A less than one-year-old B2B software startup in Houston is beefing up its offerings with a new feature that thrusts it into the rapidly growing fintech space.

RepeatMD, founded in December 2020, specializes in white-label rewards apps for plastic surgeons, medical spas, dermatologists, and similar businesses. Now, it's expanding into the "buy now, pay later" fintech realm through a new deal with BTL Industries, a Marlborough, Massachusetts-based provider of body-sculpting equipment.

RepeatMD's new Medical Gym function enables customers treated with BTL equipment to finance add-on enhancement and maintenance packages through "buy now, pay later" (BNPL) arrangements. BNPL is a booming sector. The size of the global BNPL market approached $90.7 billion in 2020 and is projected to come close to $4 trillion by 2030, according to Allied Market Research.

RepeatMD essentially layers the Medical Gym's BNPL functionality on top of the rewards feature of its apps.

Chris Chomenko, vice president of sales at RepeatMD, says the startup already had been working on a BNPL offering when BTL approached the RepeatMD team about creating a BNPL product. RepeatMD and BTL share many of the same clients.

"We are rolling out with them nationally at a breakneck speed because the demand they have from their client base is so high," Chomenko says. "It's kind of forcing us to do in three months what we planned on doing in three years."

While the concept of a rewards app or a BNPL program is not unique, their pairing is, according to Chomenko. Sitter calls the marriage of the two a "game changer" — a game changer that eventually should extend well beyond BTL's clients.

RepeatMD founder and CEO Philipp Sitter says the Medical Gym feature lets customers break up the cost of, say, a $5,000 treatment into management monthly payments. The results of a survey of RepeatMD app users found that the guilt of putting down a wad of cash on aesthetics services was the No. 2 barrier cited in terms of spending money on treatments.

"What we'll be working on is being a full, proper fintech play, where we have that buy now, pay later functionality, and doctors can get paid in advance for treatments. But that is a large endeavor that will take us all of a year to [complete]," Chomenko says.

RepeatMD counts more than 600 practices in North America as customers. The startup envisions that figure rising to 1,000 by the end of this year. In tandem with that growth, RepeatMD foresees revenue climbing to eight figures (at least $10 million) by the end of 2022 and its valuation growing to nine figures (at least $100 million) by then.

Today, RepeatMD employs about 30 people. Sitter says the headcount should reach 75 to 100 by the end of next year.

Sitter is self-funding RepeatMD with proceeds from other business ventures, including Houston-based food and beverage loyalty and rewards platform VIPinsiders and Houston-based brunch and lunch restaurant EggHaus Gourmet. However, RepeatMD plans to raise outside capital in the first quarter of 2022.

The company sets up each client with an exclusive private-label app. RepeatMD says businesses using its app have seen an average sales increase of $313,000 and an average of 51 new referrals within the first 90 days of adopting the app.

Sitter says the RepeatMD rewards app provides a "gateway" for businesses to drum up repeat business and sell more services, much like the Starbucks rewards app incentivizes customers to try different food and beverage products.

"We see us becoming ubiquitous in the industry, where anybody that's a dermatologist, a plastic surgeon, or a medical spa has [our app]," Sitter says.

"We look at mobile app experience as something that's coming for all the local businesses. We're just the frontrunners in bringing it to the masses," he adds.

Philipp Sitter is the founder of RepeatMD. Photo via LinkedIIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.